Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
Journal
Liver cancer
Journal Volume
12
Journal Issue
4
Date Issued
2023-09
Author(s)
Merle, Philippe
Kudo, Masatoshi
Edeline, Julien
Bouattour, Mohamed
Chan, Stephen L
Yau, Thomas
Garrido, Marcelo
Knox, Jennifer
Daniele, Bruno
Breder, Valeriy
Lim, Ho Yeong
Ogasawara, Sadahisa
Cattan, Stéphane
Chao, Yee
Siegel, Abby B
Martinez-Forero, Iván
Wei, Ziwen
Liu, Chih-Chin
Finn, Richard S
Abstract
KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported.
Subjects
Hepatocellular carcinoma; Long-term follow-up; Pembrolizumab; Programmed cell death protein 1
SDGs
Type
journal article